Business Wire

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Yahoo Finance

Ensoma to Present Clinical Safety Data from First Participant Dosed with In Vivo HSC Engineering Therapy at ASGCT Annual Meeting

Initial Phase 1/2 safety data for EN-374 in X-linked chronic granulomatous disease (X-CGD) demonstrate tolerability in first trial participant Updated preclinical data with Ensoma’s virus-like ...
Labroots

Monoclonality Assurance Using CloneSelect Single-Cell Printer and CloneSelect Imager in Human Stem Cell (hSC) Engineering Workflow

In recent years regenerative cell therapy utilizing the pluripotency of hESCs or iPSCs is gaining its ground and holds promise to outpace conventional treatment options for cardiac, kidney, liver, ...
Nature

Immunological barriers to haematopoietic stem cell gene therapy

Cell and gene therapies using haematopoietic stem cells (HSCs) epitomize the transformative potential of regenerative medicine. Recent clinical successes for gene therapies involving autologous HSC ...